Related Experiment Video

Updated: Jun 1, 2026

Generation of Human Nasal Epithelial Cell Spheroids for Individualized Cystic Fibrosis Transmembrane Conductance Regulator Study
08:00

Generation of Human Nasal Epithelial Cell Spheroids for Individualized Cystic Fibrosis Transmembrane Conductance Regulator Study

Published on: April 11, 2018

Design of gene therapy trials in CF patients

Jane C Davies1, Eric W F W Alton

  • 1Department of Gene Therapy, Imperial College London, SW3 6LR, London, UK. j.c.davies@imperial.ac.uk

Methods in Molecular Biology (Clifton, N.J.)
|May 20, 2011
PubMed

Insights

Gene therapy for cystic fibrosis (CF) has shown partial success in trials since 1993. This report discusses optimizing delivery methods and outcome measures to achieve clinical benefit for CFTR gene therapy.

Area of Science:

  • Medical Research
  • Biotechnology
  • Genetics

Background:

  • The first cystic fibrosis (CF) gene therapy trials began in 1993, utilizing various viral and non-viral gene transfer agents.
  • Over 20 clinical trials have explored gene therapy for CF, primarily focusing on single-dose delivery to the respiratory tract.
  • Previous trials reported successful transgene mRNA expression and partial correction of chloride secretion, but failed to improve sodium hyperabsorption.

Purpose of the Study:

  • To evaluate the translation of proof-of-principle measures into clinical benefit for CFTR gene therapy.
  • To discuss considerations in designing a clinical program for CF gene therapy.
  • To identify optimal delivery methods and outcome measures for future CF gene therapy trials.

Main Methods:

  • Review of past clinical trials and outcome measures in CF gene therapy.
  • Discussion of current strategies for optimizing gene transfer delivery methods.
  • Exploration of established and novel outcome measures for assessing clinical benefit.

Main Results:

  • Gene therapy has demonstrated transgene mRNA expression and partial correction of chloride secretion in CF patients.
  • Significant improvement in sodium hyperabsorption has not been achieved in previous trials.
  • The UK CF Gene Therapy Consortium is developing a clinical program to assess real-world efficacy.

Conclusions:

  • Translating initial gene therapy successes into tangible clinical benefits for CF patients remains a challenge.
  • Careful selection of delivery methods and outcome measures is crucial for designing effective clinical programs.
  • Future strategies may involve exploring alternative approaches to overcome current limitations in CF gene therapy.

More Related Videos

Forskolin-induced Swelling in Intestinal Organoids: An In Vitro Assay for Assessing Drug Response in Cystic Fibrosis Patients07:04

Forskolin-induced Swelling in Intestinal Organoids: An In Vitro Assay for Assessing Drug Response in Cystic Fibrosis Patients

Published on: February 11, 2017

Chimeric Antigen Receptor T Cell Manufacturing on an Automated Cell Processor06:18

Chimeric Antigen Receptor T Cell Manufacturing on an Automated Cell Processor

Published on: August 18, 2023

Related Concept Videos

Gene Therapy00:59

Gene Therapy

Gene therapy is a technique where a gene is inserted into a person’s cells to prevent or treat a serious disease. The added gene may be a healthy version of the gene that is mutated in the patient, or it could be a different gene that inactivates or compensates for the patient’s disease-causing gene. For example, in patients with severe combined immunodeficiency (SCID) due to a mutation in the gene for the enzyme adenosine deaminase, a functioning version of the gene can be inserted. The...
Gene Therapy00:59

Gene Therapy

Gene therapy is a technique where a gene is inserted into a person’s cells to prevent or treat a serious disease. The added gene may be a healthy version of the gene that is mutated in the patient, or it could be a different gene that inactivates or compensates for the patient’s disease-causing gene. For example, in patients with severe combined immunodeficiency (SCID) due to a mutation in the gene for the enzyme adenosine deaminase, a functioning version of the gene can be inserted. The...
Cystic Fibrosis: Management01:24

Cystic Fibrosis: Management

Cystic fibrosis (CF) is an autosomal recessive disorder that predominantly affects individuals of Northern European descent, occurring at a rate of 1 in 3500. It is caused by a genetic mutation in a gene on chromosome 7, most commonly the ΔF508 mutation, that codes for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. This results in thicker mucus secretions and obstruction pathologies in multiple organs, including the lungs and sinuses.
Sinus disease and chronic sinusitis...
Cystic Fibrosis: Pathogenesis01:23

Cystic Fibrosis: Pathogenesis

Cystic fibrosis (CF), an autosomal recessive disorder, significantly affects the function of exocrine glands. This genetically inherited disease is characterized by the production of thick and sticky mucus, which can severely affect various organs and systems in the body.
CF is primarily caused by a genetic mutation in a chromosome 7 gene coding for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. The most common gene mutation leading to CF is the ΔF508 mutation, but...
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...